Who founded Indapta Therapeutics?

Indapta Therapeutics was founded by Guy DiPierro, Sungjin Kim, John Sunwoo.

Who are Indapta Therapeutics's investors?

Indapta Therapeutics's investors include Leaps by Bayer, RA Capital, Vertex Ventures HC.

How much funding has Indapta Therapeutics raised?

Indapta Therapeutics has disclosed $84.4M raised across 2 rounds.

Where is Indapta Therapeutics headquartered?

Indapta Therapeutics is headquartered in Houston, US.

Indapta Therapeutics

Houston, US · Delaware corporation · 3 known investors

indapta.com ↗

Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases. Its lead candidate IDP-023 is being tested in clinical trials for indications such as multiple myeloma, non-Hodgkin's lymphoma, and progressive multiple sclerosis.

BiotechHealthtech

Founders & leadership

Guy DiPierroChief Operating Officer & Co-Founder

Sungjin KimScientific Founder

John SunwooScientific Founder

Mark FrohlichExecutive

Mark W. FrohlichChief Executive Officer

Stefanie Mandl-CashmanActing Chief Scientific Officer

Board

Lori HuBoard director

Fabio PucciBoard director

Laura StoppelBoard director

Ronald MartellChairman of the Board and Co-Founder

Investors · 3

Leaps by Bayer✓ verifiedLeverkusen

RA Capital✓ verifiedBoston

Vertex Ventures HC✓ verifiedSingapore · $500K – $10M

Reported raises · per SEC filings

Form D private placements

$84.4M disclosed across 2 rounds · 2022–2025

▶$50.8MraisedOct 2025 · 46 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Lori HuDirector
Fabio PucciDirector
Ronald MartellDirector
Mark FrohlichExecutive Officer, Director

Offering amount: $51.6M
Amount sold: $50.8M
First sale: Sep 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$33.6MraisedFeb 2022 · 37 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Mark FrohlichExecutive Officer, Director
Ronald MartellDirector
Fabio PucciDirector
Laura StoppelDirector
Guy DiPierroExecutive Officer
Lori HuDirector

Offering amount: $67.1M
Amount sold: $33.6M
Sales commissions: $2.4M
First sale: Jan 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Bioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Indapta Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Indapta Therapeutics do?: Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases. Its lead candidate IDP-023 is being tested in clinical trials for indications such as multiple myeloma, non-Hodgkin's lymphoma, and progressive multiple sclerosis.
Who founded Indapta Therapeutics?: Indapta Therapeutics was founded by Guy DiPierro, Sungjin Kim, John Sunwoo.
Who are Indapta Therapeutics's investors?: Indapta Therapeutics's investors include Leaps by Bayer, RA Capital, Vertex Ventures HC.
How much funding has Indapta Therapeutics raised?: Indapta Therapeutics has disclosed $84.4M raised across 2 rounds.
Where is Indapta Therapeutics headquartered?: Indapta Therapeutics is headquartered in Houston, US.